---
layout: default
title: Clomipramine
description: "Clomipramine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 50
evidence_level: L1
indication_count: 10
---

# Clomipramine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Clomipramine è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Clomipramine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Clomipramine æ˜¯ç¶“å…¸çš„ä¸‰ç’°æŠ—æ†‚é¬±åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å°ç„¦æ…®ç—‡æœ‰ç™‚æ•ˆï¼Œé€™èˆ‡å…¶å·²çŸ¥çš„è—¥ç†ä½œç”¨åŠè±å¯Œçš„è‡¨åºŠè­‰æ“šé«˜åº¦å»åˆï¼Œå±¬æ–¼è­‰æ“šå……è¶³çš„ã€Œè€è—¥æ—¢æœ‰ç”¨é€”ã€ã€‚
</p>

---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Clomipramine (å¯æ´›ç±³æ™®æ˜) |
| DrugBank ID | DB01242 |
| å°ç£å•†å“å | å€æ¬£è†œè¡£éŒ  25 å…¬çµ² ç­‰å¤šç¨®è£½åŠ‘ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | æ†‚é¬±ç—‡ã€å¼·è¿«ç—‡ã€ææ‡¼ç—‡ã€é©šæ‡¼ç™¼ä½œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | ç„¦æ…®ç—‡ã€obsessive-compulsive disorderã€benign paroxysmal torticollis of infancyã€schizotypal personality disorderã€histrionic personality disorder (disease)ã€paranoid personality disorderã€schizoid personality disorderã€agoraphobiaã€major depressive disorderã€endogenous depression |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.999 (anxiety disorder) |
| è­‰æ“šç­‰ç´š | L1-L2 (å¤šå€‹ RCT/ç³»çµ±æ€§å›é¡§) |

---



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. anxiety disorder</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.93%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Clomipramine çš„è—¥ç†æ©Ÿè½‰å®Œå…¨æ”¯æŒå…¶å°ç„¦æ…®ç—‡çš„ç™‚æ•ˆï¼š</p>

<ol>
<li><strong>è¡€æ¸…ç´ å†å¸æ”¶æŠ‘åˆ¶</strong>ï¼šClomipramine æ˜¯ä¸‰ç’°æŠ—æ†‚é¬±åŠ‘ä¸­è¡€æ¸…ç´ é¸æ“‡æ€§æœ€é«˜è€…ï¼Œå…¶æ´»æ€§ä»£è¬ç‰© desmethylclomipramine å‰‡æŠ‘åˆ¶æ­£è…ä¸Šè…ºç´ å†å¸æ”¶</li>
<li><strong>æŠ—ç„¦æ…®æ©Ÿè½‰æ˜ç¢º</strong>ï¼šè¡€æ¸…ç´ ç³»çµ±å¤±èª¿æ˜¯ç„¦æ…®ç—‡çš„æ ¸å¿ƒç—…ç†æ©Ÿè½‰ï¼Œå¢åŠ è¡€æ¸…ç´ å‚³å°å¯æ”¹å–„ç„¦æ…®ç—‡ç‹€</li>
<li><strong>è‡¨åºŠç¶“é©—è±å¯Œ</strong>ï¼šClomipramine å·²å»£æ³›ç”¨æ–¼å¼·è¿«ç—‡ (OCD)ã€ææ…Œç—‡ç­‰ç„¦æ…®ç›¸é—œç–¾æ‚£ï¼Œç™‚æ•ˆç¢ºç«‹</li>

</ol>
<p>å¯¦éš›ä¸Šï¼Œã€Œç„¦æ…®ç—‡ã€çš„é æ¸¬åæ˜ çš„æ˜¯ clomipramine å·²çŸ¥çš„æ²»ç™‚è­œç³»ï¼Œè€ŒéçœŸæ­£çš„æ–°é©æ‡‰ç—‡ç™¼ç¾ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>### ä»£è¡¨æ€§è‡¨åºŠè©¦é©—</p>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>æ¨™é¡Œ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03299166</td>
<td>Troriluzole è¼”åŠ©æ²»ç™‚ OCD</td>
<td>Phase 2/3</td>
<td>å·²å®Œæˆ</td>
<td>è©•ä¼°å° SSRI/clomipramine åæ‡‰ä¸ä½³æ‚£è€…çš„è¼”åŠ©æ²»ç™‚</td>
</tr>
<tr>
<td>NCT00004310</td>
<td>IV vs Oral Clomipramine in OCD</td>
<td>Phase 2</td>
<td>ç‹€æ…‹ä¸æ˜</td>
<td>æ¯”è¼ƒéœè„ˆæ³¨å°„èˆ‡å£æœ clomipramine ç™‚æ•ˆ</td>
</tr>
<tr>
<td>NCT00466609</td>
<td>OCD åŠ å¼·æ²»ç™‚ç­–ç•¥</td>
<td>Phase 4</td>
<td>å·²å®Œæˆ</td>
<td>æ¯”è¼ƒ fluoxetine + clomipramine vs fluoxetine + quetiapine</td>
</tr>
<tr>
<td>NCT00074815</td>
<td>å…’ç«¥ OCD çš„ SRI éƒ¨åˆ†åæ‡‰è€…æ²»ç™‚</td>
<td>Phase 3</td>
<td>å·²å®Œæˆ</td>
<td>èªçŸ¥è¡Œç‚ºæ²»ç™‚å¯æ”¹å–„ SRI æ²»ç™‚æ•ˆæœ</td>
</tr>
</tbody>
</table>

<p><strong>é—œéµç™¼ç¾</strong>ï¼šå¤šé …è‡¨åºŠè©¦é©—è­‰å¯¦ clomipramine å°å¼·è¿«ç—‡åŠç›¸é—œç„¦æ…®ç–¾æ‚£æœ‰æ•ˆï¼Œæ˜¯ OCD æ²»ç™‚çš„ä¸€ç·šè—¥ç‰©é¸æ“‡ã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>### ç³»çµ±æ€§å›é¡§èˆ‡ Meta åˆ†æ</p>

<table>
<thead>
<tr>
<th>PMID</th>
<th>æ¨™é¡Œ</th>
<th>å¹´ä»½</th>
<th>ä¸»è¦çµè«–</th>
</tr>
</thead>
<tbody>
<tr>
<td>38014714</td>
<td>Pharmacological treatments in panic disorder - network meta-analysis</td>
<td>2023</td>
<td>Clomipramine æ˜¯ææ…Œç—‡æœ‰æ•ˆæ²»ç™‚é¸é …</td>
</tr>
<tr>
<td>34582562</td>
<td>Pharmacotherapy for trichotillomania</td>
<td>2021</td>
<td>Clomipramine å°æ‹”æ¯›ç—‡æœ‰æ•ˆ</td>
</tr>
<tr>
<td>27663940</td>
<td>SSRI and Clomipramine in Pediatric OCD - meta-analysis</td>
<td>2016</td>
<td>ç¢ºèª clomipramine å°å…’ç«¥ OCD æœ‰æ•ˆ</td>
</tr>
<tr>
<td>25681005</td>
<td>OCD: Practical strategies for pharmacological treatment</td>
<td>2015</td>
<td>Clomipramine èˆ‡ SSRI ç‚º OCD ä¸€ç·šæ²»ç™‚</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. benign paroxysmal torticollis of infancy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. schizotypal personality disorder</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ5 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11893994/" target="_blank">11893994</a></td><td>2002</td><td>Article</td><td>Comprehensive psychi</td><td>Obsessive-compulsive disorder with poor insight.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2265532/" target="_blank">2265532</a></td><td>1990</td><td>Article</td><td>Comprehensive psychi</td><td>Correlates of DSM-III personality disorder in obsessive-comp...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1444723/" target="_blank">1444723</a></td><td>1992</td><td>Article</td><td>Archives of general </td><td>Effect of axis II diagnoses on treatment outcome with clomip...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7635854/" target="_blank">7635854</a></td><td>1995</td><td>Article</td><td>The Journal of clini</td><td>Predictors of drug treatment response in obsessive-compulsiv...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10897982/" target="_blank">10897982</a></td><td>1999</td><td>Article</td><td>MMW Fortschritte der</td><td>[Drug treatment of obsessive-compulsive disorder. With prope...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. histrionic personality disorder (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. paranoid personality disorder</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ2 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2265532/" target="_blank">2265532</a></td><td>1990</td><td>Article</td><td>Comprehensive psychi</td><td>Correlates of DSM-III personality disorder in obsessive-comp...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11407273/" target="_blank">11407273</a></td><td>2001</td><td>Article</td><td>L&#x27;Encephale</td><td>[Psychiatric manifestations of a new variant of Creutzfeldt-...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. schizoid personality disorder</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9316681/" target="_blank">9316681</a></td><td>1994</td><td>Article</td><td>Clinical neuropharma</td><td>Clomipramine-induced tourettism in obsessive-compulsive diso...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. agoraphobia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.87%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38014714/" target="_blank">38014714</a></td><td>2023</td><td>Article</td><td>The Cochrane databas</td><td>Pharmacological treatments in panic disorder in adults: a ne...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6373161/" target="_blank">6373161</a></td><td>1984</td><td>Article</td><td>Current medical rese</td><td>Clomipramine and diazepam in the treatment of agoraphobia an...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22204483/" target="_blank">22204483</a></td><td>2012</td><td>Article</td><td>Current topics in me</td><td>Treatment strategies of obsessive-compulsive disorder and pa...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22290995/" target="_blank">22290995</a></td><td>1993</td><td>Article</td><td>Journal of psychopha</td><td>Clomipramine, a better reference drug for panic/agoraphobia....</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10221358/" target="_blank">10221358</a></td><td>1999</td><td>Article</td><td>Journal of psychopha</td><td>Serum levels of clomipramine and desmethylclomipramine and c...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. major depressive disorder</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.77%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ10 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00944996" target="_blank">NCT00944996</a></td><td>NA</td><td>COMPLETED</td><td>100</td><td>Assessment of PACAP-BDNF Signaling System Involvement in Etiology and Treatment ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00704860" target="_blank">NCT00704860</a></td><td>PHASE4</td><td>COMPLETED</td><td>27</td><td>Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06942494" target="_blank">NCT06942494</a></td><td>NA</td><td>RECRUITING</td><td>88</td><td>Effect of a Family-Based Cognitive Behavioral Therapy Self-Help Intervention for...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01305707" target="_blank">NCT01305707</a></td><td>PHASE4</td><td>TERMINATED</td><td>104</td><td>Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Ph...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05931965" target="_blank">NCT05931965</a></td><td>NA</td><td>COMPLETED</td><td>88</td><td>Comparative Efficacy of Antidepressants With L-methylfolate, B12, and Magnesium ...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 5 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29477251/" target="_blank">29477251</a></td><td>2018</td><td>Article</td><td>Lancet (London, Engl</td><td>Comparative efficacy and acceptability of 21 antidepressant ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27289172/" target="_blank">27289172</a></td><td>2016</td><td>Article</td><td>Lancet (London, Engl</td><td>Comparative efficacy and tolerability of antidepressants for...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25911132/" target="_blank">25911132</a></td><td>2015</td><td>Article</td><td>Journal of affective</td><td>Dose equivalents of antidepressants: Evidence-based recommen...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28850959/" target="_blank">28850959</a></td><td>2018</td><td>Article</td><td>Pharmacopsychiatry</td><td>Epileptic Seizures Under Antidepressive Drug Treatment: Syst...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30611836/" target="_blank">30611836</a></td><td>2019</td><td>Article</td><td>Progress in neuro-ps</td><td>Pharmacological interventions targeting anhedonia in patient...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. endogenous depression</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.71%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27289172/" target="_blank">27289172</a></td><td>2016</td><td>Article</td><td>Lancet (London, Engl</td><td>Comparative efficacy and tolerability of antidepressants for...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2669440/" target="_blank">2669440</a></td><td>1989</td><td>Article</td><td>Acta psychiatrica Sc</td><td>Moclobemide and clomipramine in endogenous depression. A ran...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2694201/" target="_blank">2694201</a></td><td>1989</td><td>Article</td><td>Psychiatry research</td><td>Clomipramine and EEG sleep in depression.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2005057/" target="_blank">2005057</a></td><td>1991</td><td>Article</td><td>Journal of the Ameri</td><td>Trichotillomania and depression.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15994726/" target="_blank">15994726</a></td><td>2005</td><td>Article</td><td>The American journal</td><td>Dysbetalipoproteinemia and clomipramine.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. attention deficit-hyperactivity disorder</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.58%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25238582/" target="_blank">25238582</a></td><td>2014</td><td>Article</td><td>The Cochrane databas</td><td>Tricyclic antidepressants for attention deficit hyperactivit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32982805/" target="_blank">32982805</a></td><td>2020</td><td>Article</td><td>Frontiers in psychia</td><td>Antidepressants in Children and Adolescents: Meta-Review of ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10418807/" target="_blank">10418807</a></td><td>1999</td><td>Article</td><td>The Journal of clini</td><td>Aggressive behavior in patients with attention-deficit/hyper...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12185806/" target="_blank">12185806</a></td><td>2002</td><td>Article</td><td>Neurologia i neuroch</td><td>[Tic syndrome].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17207050/" target="_blank">17207050</a></td><td>2007</td><td>Article</td><td>Journal of paediatri</td><td>Drug therapy for attention-deficit/hyperactivity disorder-li...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | é©æ‡‰ç—‡ | åŠ‘å‹ | ç‹€æ…‹ |
|------------|--------|--------|------|------|
| å¤šé …è¨±å¯è­‰ | å€æ¬£è†œè¡£éŒ ç­‰ | æ†‚é¬±ç—…ã€å¼·è¿«ç—‡ã€ææ‡¼ç—‡ã€é©šæ‡¼ç™¼ä½œ | éŒ åŠ‘/è† å›Š | æœ‰æ•ˆ |

**å‚™è¨»**ï¼šå°ç£æ ¸å‡†é©æ‡‰ç—‡å·²åŒ…å«ã€Œææ‡¼ç—‡ã€åŠã€Œé©šæ‡¼ç™¼ä½œã€ï¼Œå¯¦è³ªä¸Šæ¶µè“‹äº†ç„¦æ…®ç—‡çš„ä¸»è¦é¡å‹ã€‚

---

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è­¦èª

1. **å¿ƒè‡Ÿæ¯’æ€§**ï¼šå¯èƒ½å»¶é•· QT é–“æœŸï¼Œå¿ƒè‡Ÿç—…æ‚£è€…éœ€è¬¹æ…ä½¿ç”¨
2. **æŠ—è†½é¹¼å‰¯ä½œç”¨**ï¼šå£ä¹¾ã€ä¾¿ç§˜ã€å°¿æ»¯ç•™ã€è¦–åŠ›æ¨¡ç³Š
3. **é®éœä½œç”¨**ï¼šå¯èƒ½å½±éŸ¿é§•é§›åŠæ“ä½œæ©Ÿæ¢°èƒ½åŠ›
4. **éé‡ä¸­æ¯’é¢¨éšª**ï¼šä¸‰ç’°æŠ—æ†‚é¬±åŠ‘éé‡å¯èƒ½è‡´å‘½
5. **å¹´è¼•äººè‡ªæ®ºé¢¨éšª**ï¼š18-24 æ­²æ‚£è€…åˆæœŸæ²»ç™‚éœ€å¯†åˆ‡ç›£æ¸¬

### è—¥ç‰©äº¤äº’ä½œç”¨æ³¨æ„äº‹é …

- **MAO æŠ‘åˆ¶åŠ‘**ï¼šç¦æ­¢ä½µç”¨ï¼Œå¯èƒ½å°è‡´è¡€æ¸…ç´ ç—‡å€™ç¾¤
- **CYP2D6 æŠ‘åˆ¶åŠ‘**ï¼šå¯èƒ½å¢åŠ  clomipramine è¡€ä¸­æ¿ƒåº¦
- **ä¸­æ¨ç¥ç¶“æŠ‘åˆ¶åŠ‘**ï¼šåŠ å¼·é®éœä½œç”¨
- **æŠ—è†½é¹¼è—¥ç‰©**ï¼šåŠ é‡æŠ—è†½é¹¼å‰¯ä½œç”¨

### CYP450 ä»£è¬è€ƒé‡

Clomipramine ç¶“ç”± CYP2C19 åŠ CYP2D6 ä»£è¬ã€‚æ–‡ç»å ±å‘Š (PMID: 28470111) é¡¯ç¤ºï¼ŒCYP2C19 åŠ CYP2D6 ä¸­é–“ä»£è¬è€…å¯èƒ½å‡ºç¾é¡¯è‘—å‡é«˜çš„è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ï¼Œå»ºè­°è€ƒæ…®è—¥ç‰©åŸºå› æª¢æ¸¬ã€‚

---




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**é…’ç²¾** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”¢ç”Ÿå”åŒä½œç”¨ã€‚
- å»ºè­°ï¼šéœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚

**è‘¡è„æŸšæ±** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©ä»£è¬ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šéœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚é¿å…é£Ÿç”¨è‘¡è„æŸšæˆ–è‘¡è„æŸšæ±ã€‚

**è”“è¶Šè“æ±** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©ä»£è¬ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šéœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šä½µç”¨å¯èƒ½å°è‡´è¡€æ¸…ç´ ç—‡å€™ç¾¤
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨

**å¡ç“¦** ğŸ”´ Major
- å½±éŸ¿ï¼šå¡ç“¦å¢å¼·ä¸­æ¨ç¥ç¶“æŠ‘åˆ¶ä½œç”¨
- å»ºè­°ï¼šé¿å…ä½µç”¨

**çºˆè‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šçºˆè‰å¯èƒ½å¢å¼·é®éœä½œç”¨
- å»ºè­°ï¼šè¬¹æ…ä½¿ç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Adrenal Gland Neoplasms** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Mania** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šPremarketing studies reported activation of mania/hypomania in patients with affective disorders treated with clomipramine...

**Bone Marrow Failure Disorders** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€è¡€æ “ã€è²§è¡€ã€‚

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**Schizophrenia** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šTricyclic antidepressants (TCAs) may aggravate symptoms of psychosis in schizophrenic patients, particularly those with paranoid symptomatology...

**Tardive Dyskinesia** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šè€å¹´äººã€‚

**Alcoholic Intoxication** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šTricyclic antidepressants can enhance the response to alcohol...

**èºé¬±ç—‡** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šA major depressive episode can be the initial presentation of bipolar disorder...

**é’å…‰çœ¼** ğŸŸ¡ Moderate
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€ç³–ã€é«˜è¡€ç³–ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šè€å¹´äººã€‚

**Neutropenia** ğŸŸ¡ Moderate
- å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Schizophrenia** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šSome tricyclic antidepressants have shown to cause activation or exacerbation of psychosis in schizophrenic patients...

**Thyroid Diseases** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå¿ƒå¾‹ä¸æ•´ã€‚

**å°¿æ»¯ç•™** ğŸŸ¡ Moderate
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**Anticholinergic Syndrome** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè¡€å£“æ§åˆ¶ä¸è‰¯ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šè€å¹´äººã€‚

**å¿ƒè¡€ç®¡ç–¾ç—…** ğŸŸ¢ Minor
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€å¿ƒå¾‹ä¸æ•´ã€è¡€æ “ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Pheochromocytoma** ğŸŸ¢ Minor
- æ³¨æ„äº‹é …ï¼šTricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines...

**Acute Myocardial Infarction Recovery** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**Depressive Disorder** ğŸŸ¢ Minor
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚ç‰¹åˆ¥æ³¨æ„æ—ç¾¤ï¼šå…’ç«¥ã€‚

**ç™²ç™‡** ğŸŸ¢ Minor
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬è©•ä¼°

| è©•ä¼°é …ç›® | çµæœ |
|----------|------|
| æ©Ÿè½‰åˆç†æ€§ | é«˜ - è¡€æ¸…ç´ /æ­£è…ä¸Šè…ºç´ å†å¸æ”¶æŠ‘åˆ¶å°ç„¦æ…®ç—‡æœ‰æ˜ç¢ºç™‚æ•ˆ |
| è‡¨åºŠè­‰æ“š | å……è¶³ - å¤šé … RCT åŠ meta-analysis æ”¯æŒ |
| æ–‡ç»æ”¯æŒ | å¼· - åœ‹éš›æŒ‡å¼•æ¨è–¦ |
| æ•´é«”è­‰æ“šç­‰ç´š | **L1-L2 (å¤šå€‹ RCT/ç³»çµ±æ€§å›é¡§)** |

### è‡¨åºŠå»ºè­°

1. **å·²å¯è‡¨åºŠä½¿ç”¨**ï¼šClomipramine å°ç„¦æ…®ç›¸é—œç–¾æ‚£ï¼ˆç‰¹åˆ¥æ˜¯ OCDã€ææ…Œç—‡ï¼‰çš„ç™‚æ•ˆå·²ç²ç¢ºèª
2. **é©æ‡‰ç—‡è€ƒé‡**ï¼šå°ç£æ ¸å‡†é©æ‡‰ç—‡å·²æ¶µè“‹å¤šç¨®ç„¦æ…®ç–¾æ‚£ï¼Œç¬¦åˆä»¿å–®é©æ‡‰ç—‡ä½¿ç”¨
3. **è™•æ–¹æ³¨æ„äº‹é …**ï¼š
   - èµ·å§‹åŠ‘é‡å®œä½ï¼Œç·©æ…¢èª¿å‡
   - ç›£æ¸¬å¿ƒé›»åœ–ï¼Œç‰¹åˆ¥æ˜¯æœ‰å¿ƒè‡Ÿç—…å²è€…
   - æ³¨æ„å¹´è¼•æ‚£è€…çš„è‡ªæ®ºé¢¨éšª
   - é¿å…çªç„¶åœè—¥

### çµèª

æ­¤é æ¸¬é©—è­‰äº† TxGNN çŸ¥è­˜åœ–è­œæ–¹æ³•èƒ½æº–ç¢ºè­˜åˆ¥è—¥ç‰©çš„å·²çŸ¥æ²»ç™‚æ½›åŠ›ã€‚Clomipramine å°ç„¦æ…®ç—‡çš„ç™‚æ•ˆå·²æœ‰å …å¯¦çš„è­‰æ“šåŸºç¤ï¼Œå±¬æ–¼ã€Œå†ç™¼ç¾ã€è€Œéã€Œæ–°ç™¼ç¾ã€ã€‚

---

*æœ¬ç­†è¨˜åƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚ä»»ä½•ç”¨è—¥æ±ºç­–æ‡‰è«®è©¢å°ˆæ¥­é†«ç™‚äººå“¡ã€‚*

*æœ€å¾Œæ›´æ–°ï¼š2026-02-11*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Amorolfine]({{ "/drugs/amorolfine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Urea]({{ "/drugs/urea/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Paclitaxel]({{ "/drugs/paclitaxel/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cobicistat]({{ "/drugs/cobicistat/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Xylometazoline]({{ "/drugs/xylometazoline/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Clomipramineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/clomipramine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_clomipramine,
  title = {Clomipramineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/clomipramine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
